Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2013

View Archived Issues

A novel potential therapy for the treatment of stress-related autoimmune skin disease

Phase III trial of arbaclofen placarbil ongoing in patients with MS-related spasticity

BreastPRS as a new prognostic panel for breast cancer

GGF2 well tolerated in patients with HF at doses up to 0.75 mg/kg

Phase I trial of PD vaccine candidate PD-01A under way

Teriparatide as the first anabolic therapy for osteogenesis imperfecta

Amakem presents novel ROCK inhibitors

Bayer presents new agents for cardiovascular disorders

Anacor Pharmaceuticals reports results from phase II AN-2728 study

Cancer research institutions collaborate with Janssen to discover multiple myeloma drug

Astellas enters agreements to research new anti-dengue virus drugs

Blueprint Medicines enters oncology collaboration

ChromoTek licenses Chromobody Technology to Bayer

Guerbet announces FDA approval for Dotarem

NDA submitted for brentuximab vedotin in Japan

Updated results from ALSYMPCA trial show survival benefit

GlaxoSmithKline designs new RORgamma modulators

Novel antifungal agents presented by Toyama Chemical and Taisho

Santhera Pharmaceuticals withdraws MAA for Raxone

Metabolex patents new GPBA receptor agonists

CHMP issues positive opinion on HyQvia

Stribild gets positive opinion in Europe

FDA approves AdreView to evaluate cardiac risk in heart failure patients

Cerulean's phase IIb study of CRLX-101 in NSCLC does not meet endpoint

European CHMP recommends approval of Aubagio for relapsing-remitting MS

EMA committee recommends approval of ponatinib for two cancer indications

CHMP recommends European approval of Biogen Idec's Tecfidera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...